|
|
|
Weekly Market- Markets consolidate this week; Nifty holds 8500
|
|
Friday, July 22, 2016 |
| | | Market Commentary | | | Markets consolidate this week; Nifty holds 8500 | | The Indian markets wrapped up the week in the red zone reversing the gaining trend of previous week. The Sensex lost 33.26 points, while the Nifty fell 0.20 points for the week ended July 22, 2016. | |
 Major Headlines for the week:
Indian indices:
Indian markets registered minute losses this week which ended on Friday, July 22, 2016. The S&P BSE Sensex settled below the psychological level of 28,000 after surpassing that level in the course of trading during the week. The broader market depicted strength. The BSE Mid-Cap index rose 1.25%. The BSE Small-Cap index rose 1.06%. Both these indices outperformed the Sense.
Among the 30-share Sensex pack, 18 stocks rose and remaining stocks declined in the week ended Friday, 22 July 2016. Bank stocks declined with the S&P BSE Bankex index losing 1.58%.
The Sensex lost 33.26 points or 0.11% to settle at 27,803.24. The Nifty 50 index fell 0.20 points to settle at 8,541.20.
Weekly market trend from July 18 - July 22, 2016:
July 18: Indian shares closed lower for a second consecutive session as investors booked profits in recent outperformers, after rising earlier on positive sentiment due to a good monsoon. The S&P BSE Sensex and CNX Nifty fell 0.32%-0.38% each.
July 19: Indian shares edged higher on Tuesday as state-run banks gained after the government said it would infuse 229.15 billion rupees ($3.41 billion) in 13 state-run banks this fiscal year as part of a previously announced plan. The S&P BSE Sensex and CNX Nifty rose 0.15%-0.23%.
July 20: Indian shares rose on Wednesday as drug makers such as Glenmark Pharmaceuticals and Aurobindo Pharma gained after getting approvals for generic versions of a blockbuster cholesterol drug in the U.S. The S&P BSE Sensex and CNX Nifty rose 0.32%-0.44% each.
July 21: Indian shares edged lower on Thursday after hitting its strongest close in nearly a year in the previous session as caution prevailed ahead of corporate results and investors awaited progress on the GST bill. The S&P BSE Sensex and CNX Nifty fell 0.74%-0.65% each
 July 22: Indian shares ended higher on Friday, although the indexes ended marginally down for the week, with corporate earnings bringing positivity into an otherwise lacklustre market. The S&P BSE Sensex and CNX Nifty rose 0.33%-0.37% each.
Global indices:
Majority of global Indices ended in the green zone barring Shanghai Composite which was down by 1.35%. Top most gainers were Hang Seng up 1.41%, Nasdaq up 0.98%, Dax100 up 0.89%, Nikkei up 0.78% and FTSE 100 up 0.46%.  Sectoral and stock screening:
The 13 sectors ended mostly higher except S&P BSE Bankex which fell 1.58% and S&P BSE CD slipped 1.22%. Top gainers: S&P BSE Oil & Gas up 2.51%, S&P BSE HC rose 1.91% and S&P BSE Auto gained 1.09%.
| | Looking at the 'A' group stocks, the top three gainers of the week were: IIFL up 14.80%, Biocon rose 14.67% and MRPL up 14.49%
Top three losers of the week were: Mindtree lost 12.63%, PNB fell 11.58% and Union Bank slipped 9.55% FII/MF activity:
The foreign institutional investors (FIIs) have been the net buyers of the Indian stocks to the tune of Rs1771.48 crore the domestic investors bought Indian shares worth Rs420.10 crore as on July 20, 2016.
| | TOP MOVERS (GROUP A) |  | | | | |
| FII/MF ACTIVITIES | | | | | | | Gross purchase | 13,399.62 | 3,931.20 | | | Gross sale | 11,628.14 | 3,511.10 | | | Net investment | 1,771.48 | 420.10 | | | | | | | | | Data as on July 20, 2016 | | | | Market Outlook for the coming week!
Next batch of Q1 June 2016 corporate results, the progress of the monsoon rains, trend in global financial markets and outcome of monetary policy review from central banks in the US and Japan will dictate near term trend on the bourses.
The market may remain volatile as traders roll over positions in the futures & options (F&O) segment from the near month July 2016 series to August 2016 series. The near month July 2016 F&O contracts are set to expire on July 28, 2016.
A number of prominent companies are scheduled to announce their Q1 June 2016 results in the last week of July 2016. Maruti Suzuki India, Zee Entertainment Enterprises, Bharti Infratel and Dr Reddy's Laboratories are scheduled to unveil Q1 results on July 26, 2016.
On the global front, the Federal Open Market Committee (FOMC) is widely expected to keep the benchmark fed funds rates unchanged after the conclusion of two-day monetary policy meeting on 26-27 July 2016. Market participant will scrutinize the Fed statement to gauge the outlook on US monetary policy. The Fed has kept the benchmark fed funds rate unchanged after raising it for the first time in nearly a decade in December 2015.
Japan's central bank Bank of Japan (BOJ) undertakes monetary policy review on 28-29 July 2016. Market expectations of aggressive monetary easing from the BOJ have receded after comments by BOJ Governor Haruhiko Kuroda. In an interview to a British radio station taped in mid-June and broadcast on July 21, 2016, Kuroda has ruled out the idea of using helicopter money -- or directly underwriting the budget deficit -- to combat deflation. | | | | To know more about our products and services, click here. |  | Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai - 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Registration details: BSE - INB/INF/INE011073351; NSE - INB/INF/INE231073330; MSEI: INB/INF-261073333, CD - INE261073330; DP-NSDL-IN-DP-NSDL-233-2003; CDSL-IN-DP-CDSL-271-2004; PMS-INP000000662; Mutual Fund-ARN 20669 ; Commodity trading through Sharekhan Commodities Pvt. Ltd.: MCX-10080 ; (MCX/TCM/CORP/0425) ; NCDEX-00132 ; (NCDEX/TCM/CORP/0142) ; NCDEX SPOT-NCDEXSPOT/116/CO/11/20626 ; For any complaints email at igc@sharekhan.com ; Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and Do's & Don'ts by MCX & NCDEX and the T & C on www.sharekhan.com before investing. | | | | Disclaimer This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. Kindly note that this document is based on technical analysis by studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.(Technical specific) This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.
The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licencing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.
The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he nor his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document.
Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.
Compliance Officer: Ms. Namita Amod Godbole; Tel: 022-6115000; For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com | | | |
|
posted by Anonymous @ 8:52 AM  |
|
|
|
|
|
